• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The efficacy and safety of Janus kinase inhibitors in patients with atopic dermatitis: A systematic review and meta-analysis.

作者信息

Chen Jingsi, Cheng Jun, Yang Huan, Tu Wei, Zhang Yan, Luo Xiaoyan, Wang Hua

机构信息

Department of Dermatology, Ministry of Education Key Laboratory of Child Development and Disorders, National Clinical Research Center for Child Health and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Children's Hospital of Chongqing Medical University, China; Chongqing Key Laboratory of Pediatrics, Chongqing, China.

Department of Spine Surgery, The Third Xiangya Hospital of Central South University, Changsha, Hunan, China.

出版信息

J Am Acad Dermatol. 2022 Aug;87(2):495-496. doi: 10.1016/j.jaad.2022.03.039. Epub 2022 Mar 28.

DOI:10.1016/j.jaad.2022.03.039
PMID:35358602
Abstract
摘要

相似文献

1
The efficacy and safety of Janus kinase inhibitors in patients with atopic dermatitis: A systematic review and meta-analysis.JAK抑制剂在特应性皮炎患者中的疗效与安全性：一项系统评价与荟萃分析。
J Am Acad Dermatol. 2022 Aug;87(2):495-496. doi: 10.1016/j.jaad.2022.03.039. Epub 2022 Mar 28.
2
Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical Trial.SHR0302，一种高选择性 Janus 激酶 1 抑制剂，在中重度特应性皮炎患者中的疗效和安全性：一项 II 期随机临床试验。
Am J Clin Dermatol. 2021 Nov;22(6):877-889. doi: 10.1007/s40257-021-00627-2. Epub 2021 Aug 9.
3
Long-term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis.地夸磷索钠滴眼液治疗干眼的随机、双盲、安慰剂对照多中心临床试验
J Dermatol. 2020 Feb;47(2):114-120. doi: 10.1111/1346-8138.15173. Epub 2019 Dec 9.
4
The effectiveness of Janus kinase inhibitors in treating atopic dermatitis: A systematic review and meta-analysis.Janus激酶抑制剂治疗特应性皮炎的有效性：一项系统评价和荟萃分析。
Dermatol Ther. 2020 Jul;33(4):e13685. doi: 10.1111/dth.13685. Epub 2020 Jul 14.
5
Safety considerations of systemic Janus kinase inhibitors in atopic dermatitis applications.在特应性皮炎应用中，全身性 Janus 激酶抑制剂的安全性考虑。
J Dermatol. 2021 Nov;48(11):1631-1639. doi: 10.1111/1346-8138.16116. Epub 2021 Aug 30.
6
The safety of systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and network meta-analysis.特应性皮炎系统使用 JAK 抑制剂的安全性：系统评价和网络荟萃分析。
Eur J Clin Pharmacol. 2022 Dec;78(12):1923-1933. doi: 10.1007/s00228-022-03400-4. Epub 2022 Oct 7.
7
The efficacy and safety of JAK inhibitors for atopic dermatitis: a systematic review and meta-analysis.JAK 抑制剂治疗特应性皮炎的疗效和安全性：系统评价和荟萃分析。
J Dermatolog Treat. 2022 Jun;33(4):1869-1877. doi: 10.1080/09546634.2021.1942422. Epub 2021 Jul 27.
8
The efficacy of Janus kinase inhibitors in patients with atopic dermatitis: A systematic review and network meta-analysis.Janus 激酶抑制剂在特应性皮炎患者中的疗效：系统评价和网络荟萃分析。
Dermatol Ther. 2021 Sep;34(5):e15098. doi: 10.1111/dth.15098. Epub 2021 Aug 25.
9
[Janus kinase inhibitors for the treatment of atopic dermatitis-evaluation of current data and practical experience].[用于治疗特应性皮炎的Janus激酶抑制剂——当前数据及实践经验评估]
Dermatologie (Heidelb). 2022 Jul;73(7):520-528. doi: 10.1007/s00105-022-05004-6. Epub 2022 May 24.
10
Topical Janus kinase inhibitors in atopic dermatitis: a safety network meta-analysis.治疗特应性皮炎的局部 Janus 激酶抑制剂：安全性网络荟萃分析。
Int J Clin Pharm. 2023 Aug;45(4):830-838. doi: 10.1007/s11096-023-01569-x. Epub 2023 Apr 19.

引用本文的文献

1
Efficacy and safety of upadacitinib in the treatment of moderate-to-severe atopic dermatitis: A systematic review.乌帕替尼治疗中重度特应性皮炎的疗效和安全性：系统评价。
PLoS One. 2024 Jul 26;19(7):e0306463. doi: 10.1371/journal.pone.0306463. eCollection 2024.
2
Janus kinase inhibitors in atopic dermatitis: an umbrella review of meta-analyses.Janus激酶抑制剂治疗特应性皮炎：一项荟萃分析的汇总评价
Front Immunol. 2024 Feb 23;15:1342810. doi: 10.3389/fimmu.2024.1342810. eCollection 2024.
3
The Emerging Safety Profile of JAK Inhibitors in Rheumatic Diseases.
风湿性疾病中 JAK 抑制剂的新兴安全性特征。
BioDrugs. 2023 Sep;37(5):625-635. doi: 10.1007/s40259-023-00612-7. Epub 2023 Jun 23.
4
Novel Therapeutic Targets for the Treatment of Atopic Dermatitis.治疗特应性皮炎的新型治疗靶点
Biomedicines. 2023 Apr 27;11(5):1303. doi: 10.3390/biomedicines11051303.
5
Topical Janus kinase inhibitors in atopic dermatitis: a safety network meta-analysis.治疗特应性皮炎的局部 Janus 激酶抑制剂：安全性网络荟萃分析。
Int J Clin Pharm. 2023 Aug;45(4):830-838. doi: 10.1007/s11096-023-01569-x. Epub 2023 Apr 19.
6
A New Horizon for Atopic Dermatitis Treatments: JAK Inhibitors.特应性皮炎治疗的新视野：JAK抑制剂。
J Pers Med. 2023 Feb 22;13(3):384. doi: 10.3390/jpm13030384.